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Abstract
Posterior cortical atrophy (PCA) represents a special clinicoradiologic syndrome characterized by progressive visuospatial
and visuoperceptual deficits. PCA and corticobasal syndrome (CBS) may share similar pathogenetic mechanisms. We
report the clinical, neuropsychological, imaging, and genetic features of a patient with initial visual problems, who
further developed other cognitive impairments and asymmetric extrapyramidal signs fitting into the diagnosis of CBS.
Genetic testing revealed homozygous for the T allele of the rs5848 GRN variant. This study provided an evidence for CBS
belonging to the clinical spectrum of GRN genetic variant and demonstrated CBS may initially present with symptoms of
PCA in rare cases.
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Posterior cortical atrophy (PCA) is a neurodegenera-
tive disorder characterized by progressive visuospatial
and visuoperceptual deficits [1]. The dynamics of its
progression and clinical outcome are not well known.
Pathological studies have shown that Alzheimer’s disease
(AD) is the most common underlying etiology of PCA.
However, a small number of cases are also reported with
other degeneration diseases [2]. The exact genetic basis
of PCA remains unclear, however, mutations have been
reported in the prion protein gene (PRNP) [3], presenilin
1 and 2 genes (PSEN1 and PSEN2) [4], microtubule-
associated protein tau gene (MAPT) [5], and progranulin
gene (GRN) [6], suggesting heterogeneity of its genetic
mechanism. Here, we describe a case of a PCA patient
with initial visual problems, who developed further cog-
nitive impairments and asymmetric extrapyramidal signs
that fitted with a diagnosis of corticobasal syndrome
(CBS).
The patient’s initial symptoms were discovered in early
2009 at the age of 52, as it was noted that he took longer
time to return home alone than before. He also began to
complain of blurred vision, but it did not affect his daily
life. Two years later, he began to suffer from progressive
spatial disorientation. He was unable to fetch objects
with either arm by visual guidance. His memory also
began to decline and sometimes he spoke not fluently.
In 2012, he exhibited problems in writing simple words,
calculating and discerning fingers. He walked more
slowly and sometimes exhibited tremor and myoclonus
of his upper limbs, especially his right side. In May
2013, he complained of deterioration and difficulty in
tracking specific objects in his visual field. He also had
difficulty in riding, dressing himself, and distinguishing
coats from pants. He urinated anywhere as he could not
find the bathroom, and he even occasionally defecated
on himself. Structural brain magnetic resonance imaging
(MRI) in a local hospital revealed cerebral atrophy, par-
ticularly in the posterior cortex (Fig. 1a, b). He was diag-
nosed with AD. After 6 months, he stopped donepezil
treatment since his symptoms got more severe.
Positive neurological system signs included reduced fa-
cial expression, increased muscle tone and bradykinesia
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especially on the right side and a little resting tremor on
his right side. His performance in neuropsychological
evaluations (Table 1) suggested that he had problems in
visual spatial, memory, language, and motor functions.
He had no significant past medical history and no family
history of dementia.
Secondary MRI revealed marked cortical atrophy
within the frontal and occipito-parietal lobes, and partial
atrophy in the bilateral parietal lobes (Fig. 1c, d).
18F-fluorodeoxyglucose positron emission tomography
(18F-FDG-PET) showed diffuse bilateral hypometabolism
in the frontal, parietal, temporal, and occipital lobes, par-
ticularly in the occipito-parietal regions (Fig. 1e, f ). Oph-
thalmology examination found that his fundus (Fig. 1g)
and intraocular pressure were normal. His visual evoked
potential was nearly normal, while his visual field and
visual acuity examinations were not completed because
of noncooperation. A laboratory blood screening test
for reversible dementia was unremarkable. Lumber
puncture showed normal cerebrospinal fluid (CSF) pres-
sure, glucose, chlorine, cell number, and protein levels.
Normal total-tau, phosphorylated-tau, and amyloid-β (Aβ)
1–42 levels were also reported in CSF. No pathogenic mu-
tations in early-onset AD-associated genes (including APP,
PS1, PS2, BACE1, and PRNP) were found. The patient’s
APOE genotype was E3/E3. However, testing for fronto-
temporal lobar degeneration (FTLD) -associated gene
(GRN, CHMP2B, FUS,MAPT, PSEN1,TARDBP and VCP)
mutations revealed a T allele of rs5848, locating in the 3′-
UTR of GRN (Fig. 1h).
Discussion
Posterior cortical atrophy is a rare clinicoradiologic neuro-
degenerative syndrome, and two sets of clinical diagnostic
criteria for PCA have been proposed [7, 8]. The core fea-
tures of disease onset, progress forms, and main clinical
manifestations are consistent, but do not illustrate its
underlying pathological, genetic, or biomarker standards.
Fig. 1 The clinical materials of the case. a-b Axial sections, T1-weighted sequences of MRI 4 years after disease onset (at 56 years of age) revealed
cerebral atrophy, particularly in the posterior cortex. c-d One and a half years later, the secondary MRI revealed much more extensive atrophy
within the frontal and occipital-parietal lobes, and bilateral partial parietal lobe. e-f 18F-FDG-PET showed diffuse bilateral hypometabolism in the
frontal, parietal, temporal, and occipital lobes, particularly in the parieto-occipital regions. g Bilateral fundus examinations were normal. h Genetic
testing showed a single nucleotide polymorphism rs5848 (c.*78C > T), located in the 3′-UTR of GRN
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In the initial phase of our case, the symptoms were
visual problems, specifically, of disorientation and
blurred vision. Over time he manifested additional
symptoms including optic ataxia, oculomotor apraxia,
right-left disorientation, acalculia, dressing apraxia,
and agraphia, fitting into the dorsal subtype of PCA.
His first cerebral MRI revealed posterior cortical atrophy,
also supporting his initial clinical diagnosis. As the disease
progressed, the patient developed further asymmetric
extrapyramidal signs and progressive global cognitive im-
pairment, but without vertical ophthalmoplegia or appar-
ent hallucinations. The second MRI revealed much more
extensive cerebral atrophy and FDG-PET confirmed hypo-
metabolism of those cortical regions. Given the history,
clinical findings, and supporting examinations, a diagnosis
of CBS was then made [9].
Besides corticobasal degeneration, CBS can also be
caused by such as progressive supranuclear palsy, AD,
Pick’s disease, FTLD with TDP-43 inclusions, mutations
in GRN or MAPT, DLB, and CJD [10]. Considering
current clinical criteria and various pathological etiologies
for PCA and CBS, there is considerable overlap, meaning
that some patients may fulfill criteria for both syndromes,
or develop from one syndrome to the other [11].
Special biomarkers such as the CSF tau:Aβ ratio may
predict pathology in CBS patients [12]. In our case, CSF
analysis revealed normal tau and Aβ1-42 levels, which
suggests low probability of AD pathology. In addition,
genetic tests identified no reported pathogenic genetic
mutations for early-onset AD, and an APOE E3/E3
genotype. FTLD-associated gene testing revealed a gen-
etic variant, rs5848 (c.*78C > T) in the 3′-UTR of the
GRN gene, which has been reported as a risk factor for
TDP-43-positive frontotemporal dementia and other
neurodegenerative diseases such as AD. The GRN
rs5848 TT genotype is reported to improve microRNA
binding efficiency to the 3′-UTR of GRN, leading to en-
hanced suppression of GRN translation and reduced
GRN expression [13]. Tartaglia et al. [14] reported a typ-
ical patient with sporadic CBS, who was homozygous
for this GRN variant (rs5848), and without mutations in
MAPT or GRN genes. Recently, Caroppo et al., [6] re-
ported a visual/ventral variant in a PCA patient carrying
a heterozygous GRN mutation. Whether this PCA pa-
tient would develop other symptoms that meet the diag-
nosis of CBS, like our case, needs longitudinal follow-up
and final autopsy evidence.
This study provides evidence for CBS belonging to the
GRN genetic variant (rs5848) clinical spectrum, and dem-
onstrates that in rare cases, CBS may initially present with
symptoms of PCA. Longitudinal follow-up is required to
ascertain the most likely etiology and determine the
clinical-genetic-pathological mechanism of the T allele of
the rs5848 polymorphism in CBS diagnosis.
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